Vitamin B12 and muscle mitochondria: what the latest research reveals

A Cornell University study published in January 2026 in The Journal of Nutrition is the first to show that vitamin B12 directly affects how skeletal muscle cells generate energy. In young mice, a B12-deficient diet cut the maximal respiratory capacity of muscle tissue by 50 percent. In aged mice, B12 supplementation doubled the activity of a key mitochondrial enzyme.

The finding matters because roughly one in four older adults in developed countries has suboptimal B12 levels. Standard blood tests can miss the milder cases. If the results hold in humans, marginal deficiency could be accelerating age-related muscle loss in ways nobody has been tracking.

B12 is an unusual vitamin even among B vitamins. It is the largest of the group and the only one that contains a metal ion, cobalt, at its center, which is why the compounds are called cobalamins. Humans cannot produce it. Bacteria and archaea synthesize it exclusively, so every molecule in your body originated from microbial fermentation. Animals pick it up from B12-producing bacteria on plants or from eating other animals.

The classic deficiency syndromes are megaloblastic anemia, where red blood cells fail to mature, and neuropathy, where the protective sheath around nerves degrades. Both take years to develop. The Cornell study suggests the effects on muscle mitochondria may operate on a shorter timeline.

How B12 affects muscle at the cellular level

Mitochondria produce energy inside cells. Skeletal muscle is packed with them because contracting muscle demands large amounts of ATP, the cellular fuel. A single muscle fiber can hold thousands of mitochondria arranged in networks that shift shape based on energy demand.

B12 acts as a cofactor for two enzymes in humans: methionine synthase and methylmalonyl-CoA mutase. Methionine synthase sits at a junction in folate-mediated one-carbon metabolism, a cycle that produces nucleotides for DNA synthesis and methylation reactions that regulate gene expression.

When B12 drops, methionine synthase stalls. The cycle backs up. The stalled cycle disrupts thymidylate production, the nucleotide thymine needed for DNA replication and repair. Without enough thymidylate, the repair machinery starts slipping uracil, a base that belongs in RNA, into mitochondrial DNA instead.

Uracil in mitochondrial DNA is a problem because mitochondria have limited repair capacity compared to the nucleus. The accumulated errors gum up the electron transport chain, the multi-enzyme assembly line that produces ATP. The end result is a measurable drop in how much energy a muscle cell can produce.

This specific mechanism is new. B12 has been linked to mitochondrial function before through its role in methylmalonyl-CoA metabolism feeding the citric acid cycle. But the DNA integrity pathway is distinct and may matter more for muscle.

What the Cornell study found

Martha Field, an associate professor in Cornell’s Division of Nutritional Sciences, led the research. First author Luisa Castillo and co-first author Katarina Heyden, both recent Cornell PhD graduates, ran the experiments alongside collaborators at the University of Alabama at Birmingham.

Experiment one used young-adult male mice fed a B12-deficient diet for seven weeks. Two genetic lines were included: mice with a partial defect in methionine synthase, making them more sensitive to B12 status, and wild-type controls. The diet had no detectable B12, an extreme that would be rare in humans but useful for establishing whether the mechanism exists.

The tibialis anterior muscle from the B12-sensitive mice showed 50 percent lower maximal respiratory capacity of the electron transport chain compared to controls. In mitochondria-rich muscle, the B12-deficient diet lowered complex I capacity by 25 percent. Uracil in mitochondrial DNA was elevated roughly tenfold in red muscle and gastrocnemius.

Experiment two looked at aging. The team studied mice between 20 and 22 months old, roughly 60 to 70 in human years. These mice had been on a standard diet and were not B12 deficient, modeling the typical older adult with adequate but perhaps suboptimal status. They received weekly intramuscular B12 injections for eight weeks.

Complex IV activity in the gastrocnemius muscle doubled compared to saline-injected controls. Complex IV is the last enzyme in the electron transport chain, and improving its activity makes the entire energy production line run more efficiently.

“This is the first study that shows B12 deficiency affects skeletal muscle mitochondrial energy production,” Field told the Cornell Chronicle. “It seems that low B12 status is associated with lower muscle mass and maybe muscle strength.”

A related paper from the same group published simultaneously in GeroScience found that B12 supplementation in aged female mice improved muscle mitochondrial content and morphology. The converging results across sexes add confidence to the core finding.

Who is at risk for low B12

The risk groups are well established. Older adults produce less stomach acid, which cuts absorption of protein-bound B12 from food. Roughly 25 percent of adults over 60 in developed countries have suboptimal B12 status, though the number varies depending on which biomarkers you use. Serum B12 alone misses cases that methylmalonic acid or homocysteine levels catch.

Vegans and vegetarians get little B12 from diet unless they supplement. Studies consistently report that 50 to 80 percent of vegans who do not supplement have deficient or marginal status. People with pernicious anemia, Crohn disease, celiac disease, or a history of gastric bypass have absorption problems that often require injections.

Several common medications also interfere with B12 absorption. Proton pump inhibitors and H2 blockers, prescribed to millions for acid reflux, reduce stomach acid and lower B12 absorption over time. Metformin, the standard first-line drug for type 2 diabetes, is linked to reduced B12 status in long-term users.

What changes with the new research is the stakes for marginal deficiency. Someone with mildly low B12 may not have anemia or neuropathy but could still have impaired mitochondrial function in muscle tissue. The Cornell study raises the question of whether some portion of sarcopenia, the age-related muscle decline that affects roughly 10 percent of adults over 60, traces back to B12 status that current screening considers acceptable.

What the evidence says about B12 supplementation

Important caveats apply. The study was done in mice. Mouse metabolism runs faster than human metabolism. The aged-mouse doses were given by intramuscular injection, not oral supplement. The young-mouse diet was completely B12-free, a level rarely seen in humans outside severe malnutrition.

Field said the work “sets the stage for a future controlled human trial.” Until that trial happens, the findings are a mechanistic clue, not a treatment recommendation.

For people already in a B12 risk group, the standard advice holds: get tested, talk to a doctor about supplementation. Oral doses of 500 to 1,000 micrograms daily are well tolerated and inexpensive. Sublingual and injectable forms exist for people with absorption issues. The RDA for most adults is 2.4 micrograms per day, but supplemental doses run much higher because only a fraction of oral B12 gets absorbed.

The study does not support healthy adults with normal B12 levels supplementing for muscle benefits. That has not been tested in humans. Claims that B12 boosts athletic performance or muscle building in people with adequate status would need their own trials.

Readers of our earlier coverage on supplements for healthy aging may notice a recurring pattern. The interventions backed by the strongest evidence tend to target specific deficiencies. Whether you benefit depends on whether you actually need more in the first place.

How future research might change the picture

The Cornell study is part of a shift in B12 research. Scientists are asking whether the vitamin plays subtler roles in metabolism, immune function, and aging beyond the classic deficiency syndromes.

A controlled human trial in older adults with marginal B12 status is the logical next step. Researchers would measure muscle function, mitochondrial markers, and performance outcomes like grip strength and gait speed. Such a trial would need several hundred participants followed for at least six months.

Positive results would carry implications beyond supplement advice. B12 screening could become routine in geriatric assessments. Clinical definitions of adequate B12 might shift.

That is still years off. The practical takeaway for today is simpler: know your B12 status, particularly if you are over 60, vegan, or taking acid-reducing medication. Correct a deficiency if you find one. Do not assume more is better when your levels are already fine. And as with any supplement, talk to your doctor first.